These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 9555548)

  • 1. Clearance of free and total serum PSA after prostatic surgery.
    Ravery V; Meulemans A; Boccon-Gibod L
    Eur Urol; 1998; 33(3):251-4. PubMed ID: 9555548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clearance of serum PSA after open surgery for benign prostatic hypertrophy, radical cystectomy, and radical prostatectomy.
    Haab F; Meulemans A; Boccon-Gibod L; Dauge MC; Delmas V; Boccon-Gibod L
    Prostate; 1995 Jun; 26(6):334-8. PubMed ID: 7540299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy.
    Richardson TD; Wojno KJ; Liang LW; Giacherio DA; England BG; Henricks WH; Schork A; Oesterling JE
    Urology; 1996 Dec; 48(6A Suppl):40-4. PubMed ID: 8973698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Free/Total PSA (F/T ratio) kinetics in patients with clinically localized prostate cancer undergoing radical prostatectomy.
    Gregorakis AK; Malovrouvas D; Stefanakis S; Petraki K; Scorilas A
    Clin Chim Acta; 2005 Jul; 357(2):196-201. PubMed ID: 15936010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum half-life time determination of free and total prostate-specific antigen following radical prostatectomy--a critical assessment.
    Brändle E; Hautmann O; Bachem M; Kleinschmidt K; Gottfried HW; Grünert A; Hautmann RE
    Urology; 1999 Apr; 53(4):722-30. PubMed ID: 10197847
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Percent of free serum prostate-specific antigen and histological findings in patients undergoing open prostatectomy for benign prostatic hyperplasia.
    Scattoni V; Raber M; Montorsi F; Da Pozzo L; Brausi M; Calori G; Freschi M; Rigatti P
    Eur Urol; 1999 Dec; 36(6):621-30. PubMed ID: 10559617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free/total prostate-specific antigen ratio--hope and controversies.
    Ravery V; Boccon-Gibod L
    Eur Urol; 1997; 31(4):385-8. PubMed ID: 9187894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
    Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
    Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of free to total prostate specific antigen ratio in serum in the diagnosis of prostatic enlargement.
    Bhuiyan AK; Kibria SA; Subhan SS
    Bangladesh Med Res Counc Bull; 2004 Aug; 30(2):51-9. PubMed ID: 15813483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Total and free PSA kinetics in patients without prostate cancer undergoing radical cystoprostatectomy.
    Gregorakis AK; Stefanakis S; Malovrouvas D; Petraki K; Gourgiotis D; Scorilas A
    Prostate; 2008 May; 68(7):759-65. PubMed ID: 18213630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
    Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
    J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia.
    Haese A; Graefen M; Noldus J; Hammerer P; Huland E; Huland H
    J Urol; 1997 Dec; 158(6):2188-92. PubMed ID: 9366341
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Is radical prostatectomy a suitable model for determination of PSA half-life?].
    Brändle E; Gottfried HW; Maier S; Flohr P; Steinbach G; Hautmann RE
    Urologe A; 1995 Sep; 34(5):419-23. PubMed ID: 7483161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario.
    Prestigiacomo AF; Lilja H; Pettersson K; Wolfert RL; Stamey TA
    J Urol; 1996 Aug; 156(2 Pt 1):350-4. PubMed ID: 8683677
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of prostate cancer and changes in prostate-specific antigen (PSA) six months after surgery for benign prostatic hyperplasia in patients with elevated PSA.
    Ozden C; Inal G; Adsan O; Yazici S; Ozturk B; Cetinkaya M
    Urol Int; 2003; 71(2):150-3. PubMed ID: 12890951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clearance rate of serum-free and total PSA following radical retropubic prostatectomy.
    Partin AW; Piantadosi S; Subong EN; Kelly CA; Hortopan S; Chan DW; Wolfert RL; Rittenhouse HG; Carter HB
    Prostate Suppl; 1996; 7():35-9. PubMed ID: 8950362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
    Egawa S; Soh S; Ohori M; Uchida T; Gohji K; Fujii A; Kuwao S; Koshiba K
    Cancer; 1997 Jan; 79(1):90-8. PubMed ID: 8988731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced expression of prostate-specific antigen in the transition zone of the prostate. A characterization following prostatectomy for benign hyperplasia.
    Recker F; Kwiatkowski MK; Pettersson K; Piironen T; Lümmen G; Huber A; Tscholl R
    Eur Urol; 1998; 33(6):549-55. PubMed ID: 9743696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.